Since the discovery of interleukin-33 (IL-33) in 2005 [1] as the ST2L ligand, the molecule has been deeply considered in inflammatory conditions, fibroproliferative diseases, autoimmune diseases, trauma, sepsis, and most recently and significantly in pulmonary and cardiovascular diseases. The gene discussed is IL1RL1; the disease is cardiovascular disorder.